In this case report we describe the course of a patient with severe traumatic brain injury who, upon withdrawal of sedation, presented the characteristic clinical signs of paroxysmal sympathetic hyperactivity and responded to the combination of dexmedetomidine infusion and oral metoprolol. We present the diagnostic and therapeutic rationale that guided our decisions and summarize the current knowledge on the topic
INTRODUCTION: Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that exhibits sedat...
Dexmedetomidine is a very selective α2-agonist that has become a popular sedative in the intensive c...
Dexmedetomidine, an α2-adrenergic agonist, can be used to perform mild to moderate sedation in criti...
A substantial minority of patients who survive an acquired brain injury develop a state of sympathet...
An individualized titration of sedative and analgesic drugs is pivotal in the late phase management ...
Sedation in neurosurgical intensive care unit is crucial as it does not merely overcome anxiety and...
Abstract Background Cerebral edema and increased intracranial pressure are of the major consequences...
Patients who survive a traumatic brain injury (TBI) can sometimes experience symptoms of excessive s...
Early and appropriate management of brain insults has significantly reduced patient morbidity and mo...
Paroxysmal autonomic instability with dystonia (PAID) is a clinical syndrome characterized by episod...
Dexmedetomidine is an alpha-2 adrenoceptor agonist which is widely used for sedation. Dexmedetomidin...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
permits unrestricted use, distribution, and reproduction in any medium, provided the original work i...
Brain injury can lead to impaired cortical inhibition of the hypothalamus, resulting in increased sy...
Paroxysmal sympathetic hyperactivity (PSH) is a hyperadrenergic syndrome that may follow acute brain...
INTRODUCTION: Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that exhibits sedat...
Dexmedetomidine is a very selective α2-agonist that has become a popular sedative in the intensive c...
Dexmedetomidine, an α2-adrenergic agonist, can be used to perform mild to moderate sedation in criti...
A substantial minority of patients who survive an acquired brain injury develop a state of sympathet...
An individualized titration of sedative and analgesic drugs is pivotal in the late phase management ...
Sedation in neurosurgical intensive care unit is crucial as it does not merely overcome anxiety and...
Abstract Background Cerebral edema and increased intracranial pressure are of the major consequences...
Patients who survive a traumatic brain injury (TBI) can sometimes experience symptoms of excessive s...
Early and appropriate management of brain insults has significantly reduced patient morbidity and mo...
Paroxysmal autonomic instability with dystonia (PAID) is a clinical syndrome characterized by episod...
Dexmedetomidine is an alpha-2 adrenoceptor agonist which is widely used for sedation. Dexmedetomidin...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
permits unrestricted use, distribution, and reproduction in any medium, provided the original work i...
Brain injury can lead to impaired cortical inhibition of the hypothalamus, resulting in increased sy...
Paroxysmal sympathetic hyperactivity (PSH) is a hyperadrenergic syndrome that may follow acute brain...
INTRODUCTION: Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that exhibits sedat...
Dexmedetomidine is a very selective α2-agonist that has become a popular sedative in the intensive c...
Dexmedetomidine, an α2-adrenergic agonist, can be used to perform mild to moderate sedation in criti...